Compound E, chemically designated as 209986-17-4, represents a significant study within the field of Alzheimer's condition research. This γ-secretase blocking agent was initially developed as a potential therapeutic treatment aimed at reducing the production of amyloid-beta peptides, which are believed to be key contributors to the formation of … Read More